ARTHEx Biotech

The ARTHEx Biotech team is heading to Budapest for the OTS Annual Meeting 2025! Join us as our Research Scientist, Argimiro Mayoral Olmos, presents: “Fatty acid–mediated uptake system enables improved oligo delivery to muscle and brain,” on Sunday, October 19th at 14:10. We’re proud to share our latest research advancing RNA therapeutics for neuromuscular diseases. Learn more here: https://lnkd.in/gmsfuA3z #OTS2025 #MyotonicDystrophy #microRNA #Biotech

October brings exciting opportunities for ARTHEx Biotech to share our vision and connect with the biotech and investment community. Our Executive Chairman & CEO, Frederic LEGROS, will participate in multiple leading events focused on innovation in genetic medicines, including the Needham & Company Private Biotech and MedTech Forum, the Chardan/Sanofi Double Helix Den, and Chardan’s 9th Annual Genetic Medicines Conference. We’re proud to advance the ARTHEx mission: developing targeted RNA medicines — and to continue the dialogue on how precision RNA therapeutics can transform patient care for rare neuromuscular disorders and areas of high unmet need. Learn more: https://lnkd.in/grUQNPEF #ArthexBiotech #RNAtherapeutics #GeneticMedicine #BiotechInnovation

ARTHEx Biotech is excited to participate in the 2025 Neuromuscular Study Group Annual Scientific Meeting (NMSG) in Stresa, Italy, taking place September 26-28, 2025. Our team will present two posters highlighting the design, innovative operational approaches, and key learnings from the first-in-human ArthemiR™ clinical study of ATX-01, our novel therapeutic for myotonic dystrophy type 1 (DM1). Learn more here: https://lnkd.in/gwjHEPU2 #MyotonicDystrophy #microRNA #Biotech #NMSG2025

We are excited to announce the successful close of an upsized $87M financing round to accelerate the growth of #ARTHEx. Learn more here: https://lnkd.in/gZS8SHJg #Biotech #RNAtherapeutics #DM1

In #DM1, we are excited to advance ATX-01 – a unique antisense therapy candidate with dual mechanism of action that both increases MBNL production and decreases toxic DMPK mRNA. This leads to significant increase of free MBNL, correction of splicing abnormalities, and ultimately clear functional improvements in animal models. With this new capital injection, ARTHEx Biotech looks forward to generating benefit for patients, while building the next generation of RNA medicines. Learn more here: https://lnkd.in/gZS8SHJg #Biotech #microRNA #RNAtherapeutics #DM1

We are pleased to welcome #bpifrance into our high-quality investor syndicate. Together with our investors, we aim to create durable value while keeping patients at the center of everything we do. Learn more here: https://lnkd.in/gZS8SHJg #Biotech #Growth #RNAtherapeutics

With this new #funding, we are well positioned to further support the clinical development of our lead program ATX-01 for #DM1, a unique therapy currently in Phase I-IIa targeting miR23b. We will also advance a broader pipeline of targeted RNA medicines beyond the muscle - into muscular, CNS, and cardiac conditions. Read more here: https://lnkd.in/gZS8SHJg #BiotechInvestment #LifeSciences #RNA

We are excited to announce the successful close of an upsized $87M financing round to accelerate the growth of #ARTHEx. The Series B extension financing was led by Bpifrance, as part of both Large Venture and InnoBio investment strategies, and joined by all existing shareholders including AdBio partners, CDTI Innovación - Centro para el Desarrollo Tecnológico y la Innovación, Columbus Venture Partners, EIC - European Innovation Council, Hadean Ventures, Invivo Partners, and Sound Bioventures. We are grateful for the support of our new and existing investors who share our vision to advance a pipeline of targeted RNA medicines to patients in need. Learn more here: https://lnkd.in/gZS8SHJg #Biotech #RNAtherapeutics #DM1

We’re pleased to share that Frederic LEGROS, Ph.D., Executive Chairman and CEO of ARTHEx Biotech, is participating in the BOFA World Medical Innovation Forum in Boston this week. We look forward to connecting with fellow innovators and investors who share our vision for building enduring biotech value. 📍 Boston | 🗓 Sept. 15–17 #WMIF #Biotech #RNAtherapeutics

September 15th is International Myotonic Dystrophy Awareness Day, and at ARTHEx Biotech, our commitment to raising awareness about Myotonic Dystrophy (DM) continues—today and every day! Our team proudly showed their support by wearing green, standing in solidarity with the DM community. Myotonic Dystrophy is a rare, multi-systemic, and inherited condition that progresses across generations, making it the most common form of adult muscular dystrophy. Yet, despite its prevalence, DM is often misdiagnosed, under-supported, and tragically, there are still no approved treatments or cures available. We invite you to join us in our mission to advocate for better support and brighter futures for those affected by DM. Together, we can make a difference! #MyotonicDystrophy #MyotonicDystrophyAwareness #SupportDM